Sharma announced a Type C meeting with the FDA scheduled for mid-May 2026, seeking feedback on protocol amendments for LP-300, focusing on patient enrollment with the EGFR exon 21 L858R mutation, ...

Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), an AI--driven, clinical--stage oncology company leveraging its proprietary RADR(R) platform to transform the cost and timeline of ...

All primary endpoints achieved with 48% clinical benefit rate at or above therapeutic dose threshold; additional positive ...

Welcome to The Esquire Endorsement. Heavily researched. Thoroughly vetted. These picks are the best way to spend your hard-earned cash. Overhead lighting should be illegal. It is an affront to the ...

The Water Lantern Festival is underway at Maryland’s National Harbor, where hundreds of people turned out Friday to participate in the opening event.